The aim of study is to evaluate the effect of oral administration of propolis on nutritional status, enzymes, matrix metalloproteinases, inflammatory, anti-inflammatory and oxidative markers and quality of life of breast cancer patients will be treated with chemotherapy. Study is the double blind clinical trial and study population are patients with stage II and III breast cancer after surgery which will undergoing chemotherapy. 70 volunteer patients aged 30-50 years with breast cancer will be referred to Tohid Hospital undergoing chemotherapy standard treatment, chemotherapy with the same drugs (adriamycin Neoadjuvant regimen of 60 mg / m2 and cyclophosphamide 600 mg / m2, four Paclitaxel training session once every two weeks and 175 mg / m2 every 3 weeks for four courses), will be included.
Patient will be divided in to placebo and propolis group with Block Randomized sampling. A week before the start of chemotherapy, Propolis will be administered in dose of 250 mg twice a day until the end of treatment (3 months) and control group will be received a placebo. Groups’ anthropocentric data, dietary intake, nutritional status, quality of life, factors affecting appetite and blood samples will be collected before and after the intervention. Serum levels of interleukins b1,2, 10, TNF-α and oxidant-antioxidant balance, matrix metalloproteinases enzymes 2 and 9, at baseline and after the intervention will be measured. Blinding will be done for the intervention and placebo groups and reviewers of the study’s variables.